[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International reported Form 4 transactions for John F. Paolini, its Chief Medical Officer and a director. The filing shows multiple equity award grants and option/RSU issuances on September 1 and 2, 2025, including 9,828 RSUs, a 39,364-share option exercisable through 08/31/2035 at a $33.49 exercise price, and several additional RSU grants tied to prior grant dates. The report also discloses sales of Class A ordinary shares on September 1 (2,841 shares at $33.49) and September 2 (835 shares at $34.28). Post-transactions beneficial ownership totals are shown for each line and all holdings are reported as direct.

Positive

• Large equity awards were granted (9,828 RSUs and a 39,364-share option), which align executive incentives with long-term shareholder value.
• Vesting schedules

Negative

• Open-market dispositions of Class A shares were reported (2,841 shares at $33.49 and 835 shares at $34.28), representing insider sales within the reported period.

Insights

Compensation Analyst

TL;DR: Routine executive compensation awards with standard multi-year vesting and concurrent small share dispositions.

The filing documents standard equity-based compensation: time-based RSUs with four-year vesting schedules and a stock option with a 10-year term and typical 25% first-year cliff then monthly vesting. These awards align management incentives with shareholders and appear to be scheduled grants rather than extraordinary retention packages. The small open-market dispositions (2,841 and 835 shares) are recorded at prices consistent with the reported exercise price, suggesting partial monetization rather than large-scale exit.

Securities Compliance Specialist

TL;DR: Form 4 reflects compliant reporting of awards and trades, including an attorney-in-fact signature.

The report lists multiple acquisition and disposition codes, with transactions reported on 09/01/2025 and 09/02/2025 and an authorized signature by an attorney-in-fact. The disclosure includes vesting schedules and exercise price details for the option, providing adequate transparency for Section 16 reporting. No badges of irregular or undisclosed derivative structures are present in the filing text provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paolini John F.

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	09/01/2025		M		1,750	A	(1)	59,153	D
Class A Ordinary Share	09/01/2025		M		1,624	A	(1)	60,777	D
Class A Ordinary Share	09/01/2025		M		2,498	A	(1)	63,275	D
Class A Ordinary Share	09/01/2025		F		2,841	D	$33.49	60,434	D
Class A Ordinary Share	09/02/2025		M		1,725	A	(1)	62,159	D
Class A Ordinary Share	09/02/2025		F		835	D	$34.28	61,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Unit	(1)	09/01/2025		A		9,828		(2)	(2)	Class A Ordinary Share	9,828	$0	9,828	D
Share Option	$33.49	09/01/2025		A		39,364		(3)	08/31/2035	Class A Ordinary Share	39,364	$0	39,364	D
Restricted Share Unit	(1)	09/01/2025		M			1,750	(4)	(2)	Class A Ordinary Share	1,750	$0	5,250	D
Restricted Share Unit	(1)	09/01/2025		M			1,624	(5)	(5)	Class A Ordinary Share	1,624	$0	3,248	D
Restricted Share Unit	(1)	09/01/2025		M			2,498	(6)	(6)	Class A Ordinary Share	2,498	$0	2,497	D
Restricted Share Unit	(1)	09/02/2025		M			1,725	(7)	(7)	Class A Ordinary Share	1,725	$0	0	D

Explanation of Responses:

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025.

3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025.

4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.

5. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.

6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021.

	/s/ Aaron Young, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What awards did John F. Paolini receive according to the KNSA Form 4?

The filing reports 9,828 RSUs, a 39,364-share option with a $33.49 exercise price (expiring 08/31/2035), and additional RSU allotments tied to prior grant dates.

Did the insider sell any KNSA shares in these transactions?

Yes. The Form 4 shows dispositions of 2,841 shares on 09/01/2025 at $33.49 and 835 shares on 09/02/2025 at $34.28.

What are the vesting terms for the RSUs reported on the Form 4?

Most RSUs vest over a four-year period with 25% vesting on each yearly anniversary of their respective grant or vesting commencement dates.

Is the option immediately exercisable and what is its term?

The option vests with 25% on the first anniversary of the vesting commencement date then monthly over 36 months; the expiration date is 08/31/2035.

Who signed the Form 4 filing?

The filing is signed by Aaron Young, Attorney-in-Fact on behalf of the reporting person, dated 09/03/2025.